Cell and gene therapies (CGTs) present a revolutionary approach to the pharmaceutical industry. However, several complexities do arise on a logistical spectrum that diverge from those of traditional pharmaceuticals.
Supply chain visibility (SCV) seems to be on everyone’s agenda right now. However, when talking to companies, it quickly becomes clear that everyone has a different picture of visibility. Basically, visibility is about knowing more than you knew before, and this is what most companies still agree on.
